HIV and Nonischemic Heart Disease

Journal of the American College of Cardiology

Volumn 69, Issue 1, 2017, Pages 83-91

  Manga, Pravin ^a   McCutcheon, Keir ^a   Tsabedze, Nqoba ^a   Vachiat, Ahmed ^a   Zachariah, Don ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

acquired immunodeficiency syndrome; antiretroviral agents; HIV associated cardiomyopathy; HIV associated pulmonary artery hypertension

Indexed keywords

ATAZANAVIR; BOSENTAN; INTERLEUKIN 1; INTERLEUKIN 6; MACITENTAN; PREDNISOLONE; RITONAVIR; SAQUINAVIR; SILDENAFIL; TUMOR NECROSIS FACTOR; ZIDOVUDINE;

ACUTE HEART FAILURE; AORTA ANEURYSM; AORTITIS; ATRIAL FIBRILLATION; BACTERIAL ENDOCARDITIS; CARDIAC MUSCLE CELL; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CD4 LYMPHOCYTE COUNT; CONGESTIVE CARDIOMYOPATHY; CONSTRICTIVE PERICARDITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EPSTEIN BARR VIRUS; FAINTNESS; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FAILURE; HEART TAMPONADE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED AORTA ANEURYSM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED AORTITIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED ATRIAL FIBRILLATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED CARDIOMYOPATHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED INFECTIVE ENDOCARDITIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED PERICARDIAL EFFUSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED PULMONARY ARTERY HYPERTENSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED VALVULAR HEART DISEASE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION SUDDEN CARDIAC DEATH; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MYOPERICARDITIS; NONHUMAN; PATHOGENESIS; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDITIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN CARDIAC DEATH; THORAX PAIN; THORAX RADIOGRAPHY; TUBERCULOSIS; TUBERCULOUS PERICARDITIS; VALVULAR HEART DISEASE; COMPLICATION; GLOBAL HEALTH; HEART DISEASES; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; RISK FACTOR;

GLOBAL HEALTH; HEART DISEASES; HIV; HIV INFECTIONS; HUMANS; PREVALENCE; RISK FACTORS;

EID: 85009067733     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.977     Document Type: Review

References (90)

1. 1 Vachiat, A., McCutcheon, K., Tsabedze, N., Zachariah, D., Manga, P., HIV and ischemic heart disease. J Am Coll Cardiol 69 (2017), 73–82.
2. 2 Magula, N.P., Mayosi, B.M., Cardiac involvement in HIV-infected people living in Africa: a review. Cardiovasc J S Afr 14 (2003), 231–237.
3. 3 Twagirumukiza, M., Nkeramihigo, E., Seminega, B., Gasakure, E., Boccara, F., Barbaro, G., Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 5 (2007), 129–137.
4. 4 Bloomfield, G.S., Alenezi, F., Barasa, F.A., Lumsden, R., Mayosi, B.M., Velazquez, E.J., Human immunodeficiency virus and heart failure in low- and middle-income countries. J Am Coll Cardiol HF 3 (2015), 579–590.
5. 5 De Castro, S., Migliau, G., Silvestri, A., et al. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J 13 (1992), 1452–1459.
6. 6 Longo-Mbenza, B., Seghers, K.V., Phuati, M., Bikangi, F.N., Mubagwa, K., Heart involvement and HIV infection in African patients: determinants of survival. Int J Cardiol 64 (1998), 63–73.
7. 7 Sliwa, K., Carrington, M.J., Becker, A., Thienemann, F., Ntsekhe, M., Stewart, S., Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 33 (2012), 866–874.
8. 8 Remick, J., Georgiopoulou, V., Marti, C., et al. Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. Circulation 129 (2014), 1781–1789.
9. 9 Mondy, K.E., Gottdiener, J., Overton, E.T., et al., for the SUN Study Investigators. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infect Dis 52 (2011), 378–386.
10. 10 Hsue, P.Y., Hunt, P.W., Ho, J.E., et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 3 (2010), 132–139.
11. 11 Grody, W.W., Cheng, L., Lewis, W., Infection of the heart by the human immunodeficiency virus. Am J Cardiol 66 (1990), 203–206.
12. 12 Goldblum, N., Daefler, S., Llana, T., Ablashi, D., Josephs, S., Salahuddin, Z., Susceptibility to HIV-1 infection of a human B-lymphoblastoid cell line, DG75, transfected with subgenomic DNA fragments of Epstein-Barr virus. Dev Biol Stand 72 (1990), 309–313.
13. 13 Shaboodien, G., Maske, C., Wainwright, H., et al. Prevalence of myocarditis and cardiotropic virus infection in Africans with HIV-associated cardiomyopathy, idiopathic dilated cardiomyopathy and heart transplant recipients: a pilot study: cardiovascular topic. Cardiovasc J Afr 24 (2013), 218–223.
14. 14 Monsuez, J.J., Escaut, L., Teicher, E., Charniot, J.C., Vittecoq, D., Cytokines in HIV-associated cardiomyopathy. Int J Cardiol 120 (2007), 150–157.
15. 15 Duprez, D.A., Neuhaus, J., Kuller, L.H., et al., for the INSIGHT SMART Study Group. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One, 7, 2012, e44454.
16. 16 Kuller, L.H., Tracy, R., Belloso, W., et al., for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med, 5, 2008, e203.
17. 17 Holloway, C.J., Ntusi, N., Suttie, J., et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation 128 (2013), 814–822.
18. 18 Thiara, D.K., Liu, C.Y., Raman, F., et al. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis 212 (2015), 1544–1551.
19. 19 Herskowitz, A., Willoughby, S., Wu, T.C., et al. Immunopathogenesis of HIV-1-associated cardiomyopathy. Clin Immunol Immunopathol 68 (1993), 234–241.
20. 20 Lewis, W., Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis 45 (2003), 305–318.
21. 21 Domanski, M.J., Sloas, M.M., Follmann, D.A., et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 127 (1995), 137–146.
22. 22 Singhal, N., Austin, J., A clinical review of micronutrients in HIV infection. J Int Assoc Physicians AIDS Care (Chic) 1 (2002), 63–75.
23. 23 Cerrato, E., D'Ascenzo, F., Biondi-Zoccai, G., et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 34 (2013), 1432–1436.
24. 24 Bijl, M., Dieleman, J.P., Simoons, M., van der Ende, M.E., Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J Acquir Immune Defic Syndr 27 (2001), 318–320.
25. 25 Hakim, J.G., Matenga, J.A., Siziya, S., Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe. Heart 76 (1996), 161–165.
26. 26 Polanco, A., Itagaki, S., Chiang, Y., Chikwe, J., Changing prevalence, profile, and outcomes of patients with HIV undergoing cardiac surgery in the United States. Am Heart J 167 (2014), 363–368.
27. 27 Castillo, J.G., Adams, D.H., Rahmanian, P.B., Filsoufi, F., [Cardiovascular surgery in patients with HIV: epidemiology, current indications, and long-term outcome]. Rev Esp Cardiol 61 (2008), 480–486.
28. 28 Heidenreich, P.A., Eisenberg, M.J., Kee, L.L., et al. Pericardial effusion in AIDS: incidence and survival. Circulation 92 (1995), 3229–3234.
29. 29 Chillo, P., Bakari, M., Lwakatare, J., Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania. Cardiovasc J Afr 23 (2012), 90–97.
30. 30 Lind, A., Reinsch, N., Neuhaus, K., et al. Pericardial effusion of HIV-infected patients? Results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res 16 (2011), 480–483.
31. 31 Hack, C.E., Ogilvie, A.C., Eisele, B., Eerenberg, A.J., Wagstaff, J., Thijs, L.G., C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 19:Suppl 1 (1993), S19–S28.
32. 32 Calabrese, L.H., Proffitt, M.R., Yen-Lieberman, B., Hobbs, R.E., Ratliff, N.B., Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann Intern Med 107 (1987), 691–692.
33. 33 Zakowski, M.F., Ianuale-Shanerman, A., Cytology of pericardial effusions in AIDS patients. Diagn Cytopathol 9 (1993), 266–269.
34. 34 Maher, D., Harries, A.D., Tuberculous pericardial effusion: a prospective clinical study in a low-resource setting—Blantyre, Malawi. Int J Tuberc Lung Dis 1 (1997), 358–364.
35. 35 Reuter, H., Burgess, L.J., Doubell, A.F., Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 133 (2005), 393–399.
36. 36 Ntsekhe, M., Wiysonge, C.S., Gumedze, F., et al. HIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational study. PLoS One, 3, 2008, e2253.
37. 37 Imazio, M., Adler, Y., Management of pericardial effusion. Eur Heart J 34 (2013), 1186–1197.
38. 38 Mayosi, B.M., Wiysonge, C.S., Ntsekhe, M., et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J 98 (2008), 36–40.
39. 39 Blanchard, D.G., Hagenhoff, C., Chow, L.C., McCann, H.A., Dittrich, H.C., Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study. J Am Coll Cardiol 17 (1991), 1270–1276.
40. 40 Mayosi, B.M., Ntsekhe, M., Bosch, J., et al., for the IMPI Trial Investigators. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 371 (2014), 1121–1130.
41. 41 Simonneau, G., Gatzoulis, M.A., Adatia, I., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62:Suppl 25 (2013), D34–D41.
42. 42 Himelman, R.B., Dohrmann, M., Goodman, P., et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 64 (1989), 1396–1399.
43. 43 Speich, R., Jenni, R., Opravil, M., Pfab, M., Russi, E.W., Primary pulmonary hypertension in HIV infection. Chest 100 (1991), 1268–1271.
44. 44 Sitbon, O., Lascoux-Combe, C., Delfraissy, J.F., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177 (2008), 108–113.
45. 45 Thienemann, F., Dzudie, A., Mocumbi, A.O., et al. Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. BMJ Open, 4, 2014, e005950.
46. 46 Mette, S.A., Palevsky, H.I., Pietra, G.G., et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 145 (1992), 1196–1200.
47. 47 Pellicelli, A.M., Palmieri, F., Cicalini, S., Petrosillo, N., Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 946 (2001), 82–94.
48. 48 Kanmogne, G.D., Primeaux, C., Grammas, P., Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 333 (2005), 1107–1115.
49. 49 Selby, V.N., Scherzer, R., Barnett, C.F., et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. AIDS 26 (2012), 1967–1969.
50. 50 Hsue, P.Y., Deeks, S.G., Farah, H.H., et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 22 (2008), 825–833.
51. 51 Galiè, N., Humbert, M., Vachiery, J.L., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 46 (2015), 903–975.
52. 52 Petitpretz, P., Brenot, F., Azarian, R., et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 89 (1994), 2722–2727.
53. 53 Degano, B., Guillaume, M., Savale, L., et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 24 (2010), 67–75.
54. 54 Zuber, J.P., Calmy, A., Evison, J.M., et al., for the Swiss HIV Cohort Study Group. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 38 (2004), 1178–1185.
55. 55 Opravil, M., Pechère, M., Speich, R., et al., for the Swiss HIV Cohort Study. HIV-associated primary pulmonary hypertension: a case control study. Am J Respir Crit Care Med 155 (1997), 990–995.
56. 56 Pugliese, A., Isnardi, D., Saini, A., Scarabelli, T., Raddino, R., Torre, D., Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 40 (2000), 282–284.
57. 57 Gary-Bobo, G., Houssaini, A., Amsellem, V., et al. Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation 122 (2010), 1937–1947.
58. 58 Schumacher, Y.O., Zdebik, A., Huonker, M., Kreisel, W., Sildenafil in HIV-related pulmonary hypertension. AIDS 15 (2001), 1747–1748.
59. 59 Sitbon, O., Gressin, V., Speich, R., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 (2004), 1212–1217.
60. 60 Dingemanse, J., van Giersbergen, P.L., Patat, A., Nilsson, P.N., Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther 15 (2010), 157–163.
61. 61 Degano, B., Yaïci, A., Le Pavec, J., et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 33 (2009), 92–98.
62. 62 Ghofrani, H.A., Friese, G., Discher, T., et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 23 (2004), 321–326.
63. 63 Nunes, H., Humbert, M., Sitbon, O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167 (2003), 1433–1439.
64. 64 Pulido, T., Adzerikho, I., Channick, R.N., et al., for the SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 (2013), 809–818.
65. 65 Reinsch, N., Esser, S., Gelbrich, G., et al. Valvular manifestations of human immunodeficiency virus infection—results from the prospective, multicenter HIV-HEART study. J Cardiovasc Med (Hagerstown) 14 (2013), 733–739.
66. 66 Gebo, K.A., Burkey, M.D., Lucas, G.M., Moore, R.D., Wilson, L.E., Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort. J Acquir Immune Defic Syndr 43 (2006), 426–432.
67. 67 Nel, S.H., Naidoo, D.P., An echocardiographic study of infective endocarditis, with special reference to patients with HIV. Cardiovasc J Afr 25 (2014), 50–57.
68. 68 Furuno, J.P., Johnson, J.K., Schweizer, M.L., et al. Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study. BMC Infect Dis, 11, 2011, 298.
69. 69 Ribera, E., Miró, J.M., Cortés, E., et al. Influence of human immunodeficiency virus 1 infection and degree of immunosuppression in the clinical characteristics and outcome of infective endocarditis in intravenous drug users. Arch Intern Med 158 (1998), 2043–2050.
70. 70 Valencia, M.E., Guinea, J., Soriano, V., et al. [Study of 164 episodes of infectious endocarditis in drug addicts: comparison of HIV positive and negative patients]. Rev Clin Esp 194 (1994), 535–539.
71. 71 Valencia, E., Miró, J., Endocarditis in the setting of HIV infection. AIDS Rev 6 (2004), 97–106.
72. 72 Nahass, R.G., Weinstein, M.P., Bartels, J., Gocke, D.J., Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and -positive patients. J Infect Dis 162 (1990), 967–970.
73. 73 Cicalini, S., Forcina, G., De Rosa, F.G., Infective endocarditis in patients with human immunodeficiency virus infection. J Infect 42 (2001), 267–271.
74. 74 Chetty, R., Batitang, S., Nair, R., Large artery vasculopathy in HIV-positive patients: another vasculitic enigma. Hum Pathol 31 (2000), 374–379.
75. 75 Tilson, M.D. 3rd, Withers, L., Arterial aneurysms in HIV patients: molecular mimicry versus direct infection?. Ann N Y Acad Sci 1085 (2006), 387–391.
76. 76 Robbs, J.V., Paruk, N., Management of HIV vasculopathy: a South African experience. Eur J Vasc Endovasc Surg 39:Suppl 1 (2010), S25–S31.
77. 77 Javed, M.A., Sheppard, M.N., Pepper, J., Aortic root dilation secondary to giant cell aortitis in a human immunodeficiency virus-positive patient. Eur J Cardiothorac Surg 30 (2006), 400–401.
78. 2 HIV Multicenter Study. Am Heart J 141 (2001), 661–670.
79. 79 Pillay, B., Ramdial, P.K., Naidoo, D.P., HIV-associated large-vessel vasculopathy: a review of the current and emerging clinicopathological spectrum in vascular surgical practice. Cardiovasc J Afr 26 (2015), 70–81.
80. 80 Tseng, Z.H., Secemsky, E.A., Dowdy, D., et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 59 (2012), 1891–1896.
81. 81 Soliman, E.Z., Prineas, R.J., Roediger, M.P., et al. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol 44 (2011), 779–785.
82. 82 Chinello, P., Lisena, F.P., Angeletti, C., Boumis, E., Papetti, F., Petrosillo, N., Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J Infect 54 (2007), 597–602.
83. 83 Singh, M., Arora, R., Jawad, E., HIV protease inhibitors induced prolongation of the QT interval: electrophysiology and clinical implications. Am J Ther 17 (2010), e193–e201.
84. 84 Hsu, J.C., Li, Y., Marcus, G.M., et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol 61 (2013), 2288–2295.
85. 85 Esterly, J.S., Darin, K.M., Gerzenshtein, L., Othman, F., Postelnick, M.J., Scarsi, K.K., Clinical implications of antiretroviral drug interactions with warfarin: a case-control study. J Antimicrob Chemother 68 (2013), 1360–1363.
86. 86 Egan, G., Hughes, C.A., Ackman, M.L., Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother 48 (2014), 734–740.
87. 87 Bates, D., Dalton, B., Gilmour, J., Kapler, J., Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine. Can J Hosp Pharm 66 (2013), 125–129.
88. 88 Lundgren, J.D., Babiker, A.G., Gordin, F., et al., for the INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
89. 89 World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations, 2016 update. 2016, World Health Organization, Geneva, Switzerland, 56 Available at: http://apps.who.int/iris/bitstream/10665/246200/1/9789241511124-eng.pdf?ua=1 Accessed October 29, 2016.
90. 90 UNAIDS. Global AIDS Update. 2016, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland, 3 Available at: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016 Accessed October 29, 2016.